Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aperon Biosystems Corp.

This article was originally published in Start Up

Executive Summary

Aperon Biosystems Corp. wants to make monitoring of nitric oxide-a reliable marker of airway inflammation--as routine for asthma patients as glucose checks are for diabetics. It is developing a low cost, noninvasive NO biosensor suitable for use at the point of care and at home for asthma self management. The company believes that regular monitoring with its device will give patients the feedback they need to better control their symptoms.

You may also be interested in...



Start-Up News October 2006

Arbios Systems and Livercyte provide assistance for the failing liver, and Aperon Biosystems takes up the asthma challenge.

NYSCC Suppliers Day Features Biotech, Sun Care, Antimicrobials Among Ingredient Innovations

DSM’s Quali Vitamin B12 and Biosyntia’s sustainably sourced biotin were among biotech-based ingredients at the New York Society of Cosmetic Chemists’ Suppliers Day in New York. Other showcased products included antimicrobials, microbiome ingredients, and zinc oxide filters for sun protection.

FDA Grants EUA To First OTC Test That Detects COVID-19, Flu, RSV

The US agency has issued an emergency use authorization to Labcorp for its over-the-counter test that detects COVID-19, flu and respiratory syncytial virus.

Topics

Related Companies

UsernamePublicRestriction

Register

MT037334

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel